Methods of treating gastrointestinal stromal tumors
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
1. A method of treating a patient suffering from a Grade 3 adverse reaction while being administered 150 mg ripretinib daily for treatment of gastrointestinal stromal tumors, comprising:
withholding administration of ripretinib for a maximum of 28 days until the adverse reaction resolves to Grade 1 or baseline; then
administering to the patient 100 mg daily ripretinib for at least 28 days.
2. The method of claim 1 , wherein, if after 28 days of 100 mg daily dosing the adverse reaction in the patient is maintained at Grade 1 or baseline, the method comprises administering 150 mg daily ripretinib to the patient.